Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

(2013) Sylvain Thépot et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

(2012) Stefan Faderl et al.   CANCER

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

(2012) Stefan Faderl et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

(2012) Ellen K. Ritchie et al.   LEUKEMIA & LYMPHOMA

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

(2011) Stefan Faderl et al.   CANCER

Azacitidine for the treatment of patients with acute myeloid leukemia

(2011) Luca Maurillo et al.   CANCER

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

(2011) Haifa K. Al-Ali et al.   LEUKEMIA & LYMPHOMA

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

(2008) S. Faderl et al.   BLOOD